reported that miR-6077 can promote the antitumor effect of anlotinib on NSCLC (non-small cell lung cancer) cells by down-regulating the expression level of GLUT-1 (glucose transporter 1) sensitivity (41). Here, SLC2A1 is linked to non-small cell lung carcinoma.